FUNDAMENTALS · Fundamentals · AU Healthcare

Island Pharmaceuticals (ILA) Fundamentals 2026 — Revenue Analysis | SniperIQ

Island Pharmaceuticals (ILA) is a AU-listed Healthcare company in Biotechnology with a market capitalization of A

04M, trading at A$0.41 on the ASX. This SniperIQ fundamentals page covers Island Pharmaceuticals's valuation, profitability (net margin -32617.6%), revenue (A
18,910 in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapA
04M
Net Margin-32617.6%
Revenue (FY25)A
18,910

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Island Pharmaceuticals's market cap?

Island Pharmaceuticals (ILA) has a market capitalization of approximately A

04M, trading at A$0.41 on the ASX. Market cap moves with the live share price.

What is Island Pharmaceuticals's P/E ratio?

Island Pharmaceuticals's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 14.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Island Pharmaceuticals?

Island Pharmaceuticals runs a net profit margin of -32617.6%, a gross margin of -3306.1%, and an operating margin of -36720.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Island Pharmaceuticals generate?

Island Pharmaceuticals reported revenue of A

18,910 for fiscal year 2025, with net income of -A$4M and earnings per share (EPS) of -0.0226. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Island Pharmaceuticals pay a dividend?

Island Pharmaceuticals does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Island Pharmaceuticals financially healthy?

Island Pharmaceuticals carries a debt-to-equity ratio of 0.00x and a current ratio of 8.40x, with a market beta of 0.12. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Island Pharmaceuticals a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Island Pharmaceuticals (ILA) the key facts are: market cap A

04M, revenue A
18,910, 52-week range 0.145-0.63. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Island Pharmaceuticals's full fundamentals live

Get Island Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Milestone Pharmaceuticals (MIST) fundamentals · Aldeyra The (ALDX) fundamentals · Black Diamond Therapeutics (BDTX) fundamentals · SomnoMed (SOM) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons